Antibacterial therapy of community-acquired pneumonia

The present article is concerned with the principles of diagnosis of pneumonia from a perspective of evidence based medicine. Data for the etiology of community-acquired pneumonia are presented. It is emphasized that the feature of the current epidemiological situation is a significant increase in the frequency of mycoplasmal and chlamydial diseases of the lower respiratory tract. The problems of choice of first-line antibiotic for treatment of pneumonia are considered. Peculiarities of spectrum of action and the use of macrolides widely used in clinics and hospitals are discussed. Advantages of dispersible form of Josamycin (Wilprafen ® solutab) are presented. The programs of antibacterial therapy of community-acquired pneumonia in outpatient and hospital settings are stated. Author presents own data for long-term experience in treatment of pneumonia.

community-acquired pneumonia, causative agent, antibacterial therapy, macrolides, dispersible tablets, Josamycin, Wilprafen ® solutab